About Sarfez Pharmaceuticals
Sarfez Pharmaceuticals is a Healthcare company based in Vienna (United States) founded in 2017 by Salim Shah. Existing drugs are reformulated for cardiovascular and kidney diseases. Its chief executive, as recorded, is Fatima Khwaja. Sarfez Pharmaceuticals offers products and services including SOAANZ. Its focus areas include Diversified Pharmaceuticals. Its legal entity in India is Sarfez Cures India Private Limited (U24299UR2017PTC007985).
Company details
Sarfez Pharmaceuticals is focused on improving existing drugs using proprietary its extended-release formulation technology primarily to treat cardiovascular and kidney diseases. The company has developed formulation technologies such as matrix-based extended-release (MEXFOR), rapid-action orally-disintegrating technology (ROTEC) self-emulsifying drug delivery system (SEEDS). Its lead candidate is an extended release diuretic is being evaluated in clinical trials. Its RD pipeline has 8 programs which are either protein inhibitors or novel loop diuretics and are at different stages of development for hypertension, cardiac fibrosis, pancreatitis, diabetic nephropathy, nephrotic syndrome and congestive heart failure. The company has the alliances with Recipharm, Hetero Syngene.
- Headquarters Vienna, United States
- Founders Salim Shah
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website sarfezpharma.com
- Social LinkedIn YouTube
- Legal Name Sarfez Cures India Private Limited
- Date of Incorporation 25 Jul, 2017
- Jurisdiction Dehradun, Uttarakhand, India
- Latest Funding Round$2.26M (USD), Grant
Sep 2017
- Investors
Associated legal entities of Sarfez Pharmaceuticals
Sarfez Pharmaceuticals operates through Sarfez Cures India Private Limited (strike off). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Sarfez Cures India Private Limited CIN U24299UR2017PTC007985 | Strike Off | 25 Jul 2017 | Dehradun, Uttarakhand | 3 | View details |
Products & Services of Sarfez Pharmaceuticals
Sarfez Pharmaceuticals offers a comprehensive portfolio of products and services, including SOAANZ.
Tablets for treating edema in heart failure and kidney disease.
Apps and channels of Sarfez Pharmaceuticals
its YouTube channel Sarfez Pharma has 8 subscribers.
Funding Insights of Sarfez Pharmaceuticals
- Total Rounds 1
- Last Round Grant — $2.26M
- First Round $2.26M
(Sep 2017)
- Investors Count 1
All 1 funding rounds of Sarfez Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2017 | $2.26M | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Sarfez Pharmaceuticals
Sarfez Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Sarfez Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Sarfez Cures India Private Limited (Sarfez Pharmaceuticals)
Sarfez Cures India Private Limited is the primary company behind Sarfez Pharmaceuticals. The board of Sarfez Cures India Private Limited currently have 3 directors; the longest-serving is Mohd Tariq Nawab, appointed in 2017.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mohd Tariq Nawab DIN 00661300 | Director | 25 Jul 2017 | 9 yrs 3 mo | Sarfez Cures India Private Limited |
| Salim Shah DIN 02324353 | Director | 25 Jul 2017 | 9 yrs 3 mo | Sarfez Cures India Private Limited |
| Fatima Shazli Khwaja DIN 02352838 | Director | 16 Oct 2017 | 9 yrs | Sarfez Cures India Private Limited |
People of Sarfez Pharmaceuticals
2 people are tracked at Sarfez Pharmaceuticals (2 in leadership).
| Name | Role | Group |
|---|---|---|
| Founder & Chairman | Leadership | |
| CEO | Leadership |
Complete people profiles for Sarfez Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sarfez Pharmaceuticals
2 dated milestones of Sarfez Pharmaceuticals, from founding to its latest funding, stage changes and deals.
- Founded Sarfez Pharmaceuticals is founded.
- Funding First funding round of $2.3M.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Sarfez Pharmaceuticals (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sarfez Pharmaceuticals
Complete news archive for Sarfez Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sarfez Pharmaceuticals
Sarfez Pharmaceuticals was founded in 2017.
Sarfez Pharmaceuticals is headquartered in Vienna, United States.
Fatima Khwaja is the CEO of Sarfez Pharmaceuticals, as recorded in our data.
Sarfez Pharmaceuticals is focused on improving existing drugs using proprietary its extended-release formulation technology primarily to treat cardiovascular and kidney diseases. The company has developed formulation technologies such as matrix-based extended-release (MEXFOR), rapid-action orally-disintegrating technology (ROTEC) self-emulsifying drug delivery system (SEEDS). Its lead candidate is an extended release diuretic is being evaluated in clinical trials. Its RD pipeline has 8 programs which are either protein inhibitors or novel loop diuretics and are at different stages of development for hypertension, cardiac fibrosis, pancreatitis, diabetic nephropathy, nephrotic syndrome and congestive heart failure. The company has the alliances with Recipharm, Hetero Syngene.
Sarfez Pharmaceuticals offers SOAANZ.
Sarfez Pharmaceuticals has 1 investor. Key investors include HHS.
Sarfez Pharmaceuticals operates through Sarfez Cures India Private Limited.
The legal entities of Sarfez Pharmaceuticals currently have 3 directors, including Fatima Shazli Khwaja, Mohd Tariq Nawab, Salim Shah.